Langerhans cell histiocytosis in a newborn

Langerhans cell histiocytosis (LCH) is a rare myeloid disorder with a variable clinical presentation, based on the activation of the MEK-ERK signaling pathway in dendritic cell precursors. The localization of pathological lesions varies: the most common sites include the skeleton, skin, posterior pituitary gland, lymph nodes, liver, spleen, bone marrow, lungs, and central nervous system [2].

This article presents a clinical case of Langerhans cell histiocytosis in a newborn delivered at the Perinatal Center of the M.E. Nikolaev Republican Hospital No. 1-NCM. At birth, the child exhibited characteristic skin lesions in the form of a bumpy, dark cherry-colored rash on the scalp, fingers, and toes, with some areas showing light inclusions and a firm texture. Over time, with treatment, the pustules and vesicles ruptured, forming ulcers, crusts, and hemorrhages. The stages of diagnosis, including histological and immunohistochemical studies (CD1a+, Langerin+, S100+), differential diagnosis, and a comprehensive treatment approach, are described in detail. Special attention is given to the challenges of diagnosing newborns and the importance of interdisciplinary collaboration.

1. Histiocytosis from Langerhans cells – a difficult diagnosis (clinical case)/ R.M. Fayzullina, R.R. Gafurova, Z.A. Shangareeva [et al.] // Doctor of Medicine. 2019.-9. P. 25-29. https://journaldoctor.ru/catalog/pediatriya/gistiotsitoz-iz-kletok-langergansa-trudnyy-diagnoz-klinicheskiy-sluchay/.

2. Clinical guidelines for the diagnosis and treatment of Langerhans cell histiocytosis in children. Ministry of Health of Russia, 2018. https://library.mededtech.ru/rest/documents/12%20Gistiotsitoz%20Langergansa_12/.

3. Results of a retrospective monocenter study of histiocytosis from Langerhans cells in children/ E.N. Volkova, G.O. Bronin, T.A. Vysotskaya [et al.] // Pediatrics, 2009. Vol. 87. No. 4. P.33-40.

4. Federal clinical guidelines for the diagnosis and treatment of histocytosis from Langerhans cells in children/ A.G.rumyantsev, A.A. Maschan, M.A.Maschan [et al.]. Moscow, 2015. Pp. 6-7. https://nodgo.org/sites/default/files/12%20Гистиоцитоз%20Лангерганса.pdf

5. Sharova N.M. Langerhans cell histiocytosis in children / N.M. Sharova, S.V. Kukalo // Clinical dermatology and venereology. 2021.- 20(5). P.21-25. https://www.mediasphera.ru/issues/klinicheskaya-dermatologiya-i-venerologiya/2021/5/1199728492021051021.

6. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis /Chakraborty R. [et al.]// Blood. 2016;128(21):2533-2537

7. Nirav H. T. Pediatric Langerhans cell histiocytosis: state of the science and future directions / H. T. Nirav, O. Abla//Clin Adv Hematol Oncol. 2019 Feb;17(2):122-131. https://pubmed.ncbi.nlm.nih.gov/30845115/

8. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages/Emile J.F. [et al.] //Blood. 2016;127(22):2672-2681

9. Vemurafenib for BRAF V600-mutant histiocytoses: analysis of efficacy and toxicity / E.L. Diamond [et al.]//j Clin Oncol. 2017;35(7): JCO2017729652.